

⁹⁰Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy

Samer Ezziddin¹, Carsten Meyer², Stanislava Kahancova¹, Torjan Haslerud¹, Winfried Willinek², Kai Wilhelm², Hans-Jürgen Biersack¹, and Hojjat Ahmadzadehfar¹

¹Nuclear Medicine, University Hospital, Bonn, Germany; and ²Radiology, University Hospital, Bonn, Germany

Previous radiation therapy of the liver is a contraindication for performing ⁹⁰Y microsphere radioembolization, and its safety after internal radiation exposure through peptide receptor radionuclide therapy (PRRT) has not yet been investigated.

Methods: We retrospectively assessed a consecutive cohort of 23 neuroendocrine tumor (NET) patients with liver-dominant metastatic disease undergoing radioembolization with ⁹⁰Y microspheres as a salvage therapy after failed PRRT. Toxicity was recorded throughout follow-up and reported according to Common Terminology Criteria for Adverse Events (version 3). Radiologic (response evaluation criteria in solid tumors), biochemical, and symptomatic responses were investigated at 3 mo after treatment, and survival analyses were performed with the Kaplan–Meier method (log-rank test, $P < 0.05$).

Results: The median follow-up period after radioembolization was 38 mo (95% confidence interval, 18–58 mo). The mean previous cumulative activity of ¹⁷⁷Lu-DOTA-octreotate was 31.8 GBq. The mean cumulative treatment activity of ⁹⁰Y microspheres was 3.4 ± 2.1 GBq, administered to the whole liver in a single session ($n = 8$ patients), in a sequential lobar fashion ($n = 10$ patients), or to only 1 liver lobe ($n = 5$ patients). Only transient, mostly minor liver toxicity (no grade 4) was recorded. One patient (4.3%) developed a gastroduodenal ulcer (grade 2). The overall response rates for radiologic, biochemical, and symptomatic responses were 30.4%, 53.8%, and 80%, respectively. The median overall survival was 29 mo (95% confidence interval, 4–54 mo) from the first radioembolization session and 54 mo (95% confidence interval, 47–61 mo) from the first PRRT cycle. A tumor proliferation index Ki-67 greater than 5% predicted shorter survival ($P = 0.007$).

Conclusion: Radioembolization is a safe and effective salvage treatment option in advanced NET patients with liver-dominant tumor burden who failed or progressed after PRRT. The lack of relevant liver toxicity despite high applied ⁹⁰Y activities and considerable previous cumulative activities of ¹⁷⁷Lu-octreotate is noteworthy and disputes internal radiation exposure by PRRT as a toxicity risk factor in subsequent radioembolization.

Key Words: neuroendocrine tumors; radioembolization; peptide receptor radionuclide therapy; ¹⁷⁷Lu-DOTA-octreotate; ⁹⁰Y microspheres

J Nucl Med 2012; 53:1663–1669

DOI: 10.2967/jnumed.112.107482

Peptide receptor radionuclide therapy (PRRT) is an effective systemic treatment modality for metastatic gastroenteropancreatic neuroendocrine tumors (NETs) and is frequently performed as a first- or second-line therapy in progressive or functionally uncontrolled disease (1,2). The compound [¹⁷⁷Lu-DOTA⁰,Tyr³]-octreotate (¹⁷⁷Lu-octreotate) is often used for this purpose, with outstanding response and survival data available (1,3). Eventually, patients will progress again after a certain period of remission or disease stabilization, and a liver-dominant metastatic pattern—qualifying the patient for liver-directed therapy—may frequently persist over the course of disease.

Radioembolization with ⁹⁰Y microspheres (⁹⁰Y-RE) is a safe and effective treatment form for unresectable liver malignancy (4,5). Liver toxicity is encountered with an overall low incidence (6–9). Known risk factors are previous intra-arterial therapy, chemotherapy, and high applied activities per target volume (7,9,10). Intraarterial delivery of β -emitting ⁹⁰Y-loaded microspheres yields tumor-targeted internal radiation depending on the preferential arterial tumor vascularization. NETs are perfectly suited for transarterial treatment, and in particular for radioembolization, because of their typically prominent hypervascularity (11–13). The efficacy and safety of ⁹⁰Y-RE have been demonstrated in this tumor entity (14–21), including patients after bland arterial embolization (22). However, no data are available on the safety of ⁹⁰Y-RE after internal radiation with targeted radionuclide treatment.

Previous external-beam therapy accounting for hepatic radiation exposure constitutes a known relative contraindication for radioembolization (23,24). Whether there is an analogy to internally induced radiation exposure implying a clinical caveat to subsequent radioembolization is of major interest for the management of NET patients. Although previous PRRT does not yet constitute a formal contraindication for performing radioembolization, the question of whether

Received Apr. 20, 2012; revision accepted Jun. 25, 2012.

For correspondence or reprints contact: Samer Ezziddin, Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Strasse 25, D-53105 Bonn, Germany.

E-mail: samer.ezziddin@ukb.uni-bonn.de

Published online Sep. 17, 2012.

COPYRIGHT © 2012 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

^{90}Y -RE is safe and effective in patients for whom PRRT has failed has not been investigated but remains of high clinical relevance. We addressed this issue with a retrospective study assessing outcome and toxicity of ^{90}Y -RE after previous PRRT.

MATERIALS AND METHODS

The efficacy and toxicity of ^{90}Y -RE in patients after previously performed PRRT was retrospectively investigated from a single-center experience. For this purpose, a review and analysis of all patients being treated with radioembolization after PRRT in our institution were performed. The study was performed in accordance with the Declaration of Helsinki and with national regulations. Patients had provided informed consent for the scientific analysis of their data. Approval by the institutional review board is not required for retrospective studies on nonexperimental interventions at the authors' institution. However, explicit approval from the local ethics committee was obtained for the prospective and retrospective assessment of outcome of NET patients throughout follow-up in our institution, including this retrospective investigation.

Patients

We evaluated 23 consecutive patients undergoing radioembolization at our institution after previous administration of PRRT. All patients had unresectable gastroenteropancreatic NET with liver-dominant disease. Apart from 1 patient, there was bilobar tumor spread. The baseline patient and tumor characteristics are given in Table 1. Inclusion criteria for radioembolization of gastroenteropancreatic NET patients were liver-dominant disease with regard to prognosis or symptoms, an Eastern Cooperative Oncology Group performance score of 0–2, an adequate liver function (bilirubin < 2 mg/dL, albumin > 3 mg/dL, no severely impaired PT/PTT), progressive or functionally uncontrolled disease despite standard treatment (surgery, chemotherapy, somatostatin analogs), absence of excessive lung shunting (<30 Gy calculated lung dose), and both favorable tumor uptake and missing intraabdominal shunting on $^{99\text{m}}\text{Tc}$ -macroaggregated albumin (MAA) imaging after diagnostic angiography. In our cohort, 19 patients were progressive by size or number according to Response Evaluation Criteria in Solid Tumors before implementation of ^{90}Y -RE, and 4 patients were treated because of persistent hormone hypersecretion. Tumor-induced ascites was not seen as a contraindication to treatment and in fact were present in 3 patients. The portal vein was patent in all patients, although portal vein occlusion was not an exclusion criterion for treatment in our institution. Informed consent was obtained from all patients before evaluation (MAA angiogram) and each radioembolization session.

PRRT

PRRT was performed with ^{177}Lu -DOTA-octreotate (^{177}Lu -octreotate) at our institution using a common methodology as described in previous reports (25,26). Inclusion criteria for treatment with PRRT were histologically confirmed, unresectable, metastatic gastroenteropancreatic NET; sufficient tracer uptake (\geq normal liver) on baseline somatostatin receptor imaging; a glomerular filtration rate of more than 30 mL/min/1.73 m²; a white blood count of $2 \times 10^9/\text{L}$ or more; and platelets more than $70 \times 10^9/\text{L}$. PRRT was performed by the administration of a mean activity of 7.9 GBq of ^{177}Lu -octreotate per treatment cycle, aimed at 4 courses at standard intervals of 3 mo (10–14 wk). The ^{177}Lu (IDB Holland) had a spe-

TABLE 1
Baseline Characteristics

Baseline variable	<i>n</i>	Percentage
Age (y)	23	100
<60	9	39
\geq 60	14	61
Performance status		
ECOG 0–1	18	79
ECOG 2	5	21
Tumor type		
Pancreatic NET	14	61
Nonpancreatic NET	9	39
Previous treatment		
Chemotherapy	8	35
Liver resection	4	17
TACE/RFA	3	13
PRRT		
>30 GBq of ^{177}Lu -octreotate	13	57
<30 GBq of ^{177}Lu -octreotate	10	43
Hepatic tumor load		
<25% liver volume	3	13
25%–50%	9	39
>50% liver volume	11	48
Extrahepatic disease		
Present	14	61
Not present	9	39
Hormonal syndrome		
Functional disease	5	22
Nonfunctional disease	18	78
Proliferation status		
Ki-67 index \leq 5%	16	70
Ki-67 index > 5%	7	30

Mean age was 58 y, and age range was 34–80 y.

ECOG = Eastern Cooperative Oncology Group; TACE = transarterial chemoembolization; RFA = radiofrequency ablation.

cific activity in the approximate range of 100–160 GBq/ μmol at the time of administration. Peptide labeling (27,28) was performed to obtain an apparent specific activity of about 54 GBq/ μmol (ratio of activity to the total amount of peptide). Nephroprotection was implemented with standard amino acid coinfusion according to the Rotterdam protocol (2.5% lysine and 2.5% arginine in 1 L of 0.9% NaCl; infusion of 250 mL/h) (29,30). Short-acting somatostatin analogs were required to be paused 1 d before administration of ^{177}Lu -octreotate and long-acting analogs a minimum of 6 wk before PRRT. Informed consent was obtained from all patients before the initiation of therapy and before the administration of each treatment cycle.

Radioembolization Procedure

The radioembolization was always performed after exclusion of any intraabdominal and excessive pulmonary (lung-shunt fraction) deposition by a pretreatment diagnostic angiogram with planar and SPECT/CT MAA imaging after an intraarterial injection of 200–400 MBq of $^{99\text{m}}\text{Tc}$ -MAA. Aberrant vessels were coil-embolized before MAA injection to depict the flow expected in the treatment session. The treatment was performed 1–2 wk after diagnostic angiography. Resin microspheres (SIR-Spheres; SIRTEX Medical) were used in 21 patients and glass microspheres (TheraSphere; MDS Nordion) in 2 patients. The liver was treated either in

a single session (whole liver, $n = 8$ patients; unilobar, $n = 5$ patients) or in a sequential lobar fashion ($n = 10$ patients). The prescription of activity was derived from the partition model (standard target dose, 120 Gy) and the body surface area method for treatment with glass and resin spheres, respectively. The administration of resin spheres was performed under intermittent or continuous fluoroscopic control; marked reduction of forward-flow or eminent stasis led to the termination of treatment, irrespective of the amount of activity given at that time point. Posttreatment ^{90}Y bremsstrahlung imaging was performed to document target accumulation. Standard periinterventional medication included dexamethasone (4 mg twice daily for 2 d), ondansetron (8 mg intravenously during treatment), and pantoprazole (40 mg daily for 2 mo). Somatostatin analog medication in patients with poorly controlled tumor function was not discontinued but frequently intensified in the peri- and postprocedural period to avoid a potential tumor lysis–induced hormonal crisis.

Assessment of Toxicity

Pre- and posttreatment laboratory tests included liver and renal function tests and complete blood counts. In addition to the outpatient laboratory tests from the referring physician every 2–3 wk for the first 2 mo and every 4 wk until 6 mo after treatment, a complete work-up was performed at regular follow-up visits in our department at 1, 3, and 6 mo after treatment. Clinical toxicities including pain, fever, fatigue, and gastrointestinal adverse events were assessed by thorough in-patient postinterventional and follow-up documentation including all recorded complaints and findings at the regular follow-up visits. The toxicity was classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE; version 3.03).

Assessment of Response to Treatment

Patients were restaged at 3 mo after treatment with CT or MRI. The radiographic imaging results were reevaluated by experienced radiologists to classify tumor response according to the Response Evaluation Criteria in Solid Tumors. Apart from this response categorization, restaging was supplemented by somatostatin-receptor imaging in 19 patients using ^{111}In -diethylenetriaminepentaacetic acid-octreotide (OctreoScan; Tyco Healthcare) or ^{68}Ga -DOTATOC PET/CT. Biochemical response was evaluated according to chromogranin A (CgA) plasma levels if they were significantly elevated at baseline (i.e., >150 ng/mL) (complete response being normalization of the CgA level [i.e., <110 ng/mL], partial response being more than 50% reduction but still elevated CgA level, stable disease being $<50\%$ change in CgA, and progressive disease being $>50\%$ increase in CgA). For the assessment of symptomatic response, frequency or intensity of symptoms related to tumor-specific hormone production, such as diarrhea and flushing in carcinoid syndrome, were documented at our institution at baseline and each follow-up visit at 1, 3, and 6 mo after treatment.

Survival Assessment and Statistical Analysis

Survival analyses were performed with the Kaplan–Meier method; overall survival (OS) was assessed from the start of radioembolization (first treatment session) and also for additional information from the start of PRRT (first treatment cycle). Any death was considered as an event for OS, irrespective of the cause. Survival outcomes were stratified by various variables and compared using the log-rank test. A P value of less than 0.05 was considered significant. SPSS software (version 18.0; SPSS) was used for all statistical calculations.

RESULTS

The median follow-up period after the first radioembolization session was 38 mo (95% confidence interval [CI], 18–58 mo). Thirteen of the 23 patients were still alive at the time of analysis. The mean treatment activity per patient was 3.4 ± 2.1 GBq, applied over 1.7 ± 1.1 treatment sessions.

The common acute adverse events within the first 3 d of treatment—abdominal pain, fever, nausea, and vomiting—were transient, and each occurred in less than 15% of the patients (grade 3), as listed in Table 2. No serious delayed toxicities according to CTCAE were noted. One of the 23 patients (4.3%) developed a gastroduodenal ulcer (CTCAE grade 2), although no apparent culprit vessel or corresponding MAA accumulation was identified on pretreatment imaging, even on retrospective review. No case of treatment-induced death or radiation-induced liver disease was observed. No hormone-related crises in functional tumors were recorded. The lung-shunt fraction was calculated to be less than 10% in all patients, and no pulmonary toxicity was observed.

Radiologic imaging at restaging yielded a partial response in 7 patients (30.4%), stable disease in 14 (60.9%), and progressive disease in 2 (8.7%). Receptor-mediated functional imaging, when performed, indicated a significant remission in 11 of 19 patients (57.9%), stable disease in 6 (31.6%), and progressive disease in 2 (10.5%). Figure 1 shows imaging results for a patient with hepatic metastases of a pancreatic NET. Biochemical response according to CgA plasma levels, when available and elevated at baseline, comprised complete response (normalization of CgA) in 1 of 13 patients (7.7%),

TABLE 2
Toxicities After Radioembolization According to CTCAE (Version 3.0) in Percentage per Patient

Characteristic	Incidence (%) of adverse events		
	None	Grades 1–2	Grades 3–4*
Liver function tests			
Bilirubin	82.6	8.7	8.7
GPT	69.6	30.4	—
Alkaline phosphatase	34.8	65.2	—
Albumin	41.2	58.8	—
INR	91.3	8.7	—
Acute adverse events			
Nausea	65.2	26.9	8.7
Vomiting	87.0	8.7	4.3
Abdominal pain	56.5	30.4	13.0
Fever	87.0	13.0	—
Other adverse events			
Ascites	65.2	34.8	—
Ulcer, gastrointestinal	95.7	4.3	—
Fatigue	69.6	21.7	8.7

*All grade 3 toxicities (no grade 4 adverse event observed in entire study).

GPT = glutamic pyruvic transaminase (alanine aminotransferase); INR = international normalized ratio of prothrombin time.




FIGURE 1. Pre- and posttreatment imaging of patient with progressive hepatic metastases (low tumor burden group; <25% liver infiltration) of pancreatic NET. Patient was treated by whole liver radioembolization in single session. MRI at baseline (A) and 3 mo after treatment (B) demonstrate partial remission. Intraprocedural angiogram (C) displays highly hypervascular tumor lesions before (left) and directly after (right) administration of ^{90}Y microspheres, illustrating minor macroembolic effect of this treatment as opposed to primarily embolic therapeutic modalities such as bland embolization.

partial response (>50% reduction of elevated CgA) in 6 patients (46.2%), stable disease in 5 patients (38.5%), and progressive disease in 1 patient (7.7%). Symptomatic control in previously uncontrolled functionality was achieved in 4 of 5 patients (80%).

The median OS after implementation of radioembolization (Fig. 2A) was 29 mo (95% CI, 4–54 mo). Median OS from the start of PRRT was 54 mo (95% CI, 47–61 mo). From all investigated baseline factors including age, performance status, tumor type, hepatic tumor load, extrahepatic disease, tumor response, previous cumulative activity of ^{177}Lu -octreotate, and administered ^{90}Y activity per liter of target liver volume, only the tumor proliferation index significantly affected OS (Table 3). Patients with a Ki-67 index of greater than 5% survived a shorter time (median OS of 8 mo; 95% CI, 5–11 mo) than the remaining patients (median OS not reached after 54 mo; $P = 0.007$); the respective Kaplan–Meier curves are depicted in Figure 2B.

DISCUSSION

Our retrospective study indicates that ^{90}Y -RE is a safe option in patients with a history of previous PRRT. The proposed restriction of ^{90}Y -RE after hepatic radiation exposure such as external-beam therapy (23,24) does not seem to apply for this kind of internal radiation. The absence of any observed




FIGURE 2. Cumulative survival after radioembolization illustrated by Kaplan–Meier curves. Median OS of entire cohort (A) was 29 mo (95% CI, 4–54 mo). When stratified by tumor proliferation index (B), median OS was 8 mo (95% CI, 5–11) in patients with index greater than 5%, whereas for Ki-67 of 5% or less, median OS was not reached after 54 mo ($P = 0.007$).

serious toxicity despite pretreatment with high applied total activities in our cohort disputes a major impact of the internally induced radiation dose and its significance for patient selection.

There is a substantial database demonstrating the efficacy of radioembolization in hepatic NET as found by prospective and retrospective studies (14–21). Most reported median OS rates range between 25 and 36 mo from treatment

TABLE 3
Univariate Analysis of Potential Factors Contributing to OS

Factor	OS (mo)		Log-rank test <i>P</i>
	Median	95% CI	
All patients	29	4–54	
Age (y)			
<60	Not reached		
≥60	27	8–46	0.871
Performance status			
ECOG 0–1	29	24–34	
ECOG > 1	8	5–11	0.142
Tumor type			
Pancreatic NET	Not reached		
Nonpancreatic NET	12	0–37	0.138
Hepatic tumor load			
≤50%	27	NA	
>50%	29	10–48	0.418
Extrahepatic disease			
Present	29	8–50	
Not present	27	NA	0.539
Ki-67 index			
≤5%	Not reached		
>5%	8	5–11	0.007
Previous ¹⁷⁷ Lu activity			
≤30 GBq	Not reached		
>30 GBq	12	0–24	0.553
⁹⁰ Y activity/targeted liver volume			
≤1.5 GBq/L	Not reached		
>1.5 GBq/L	27	2–52	0.674
Tumor response			
Remission (partial response)	Not reached		
No remission	12	0–25	0.183

ECOG = Eastern Cooperative Oncology Group; NA = not available because of censored cases.

(14,16,18,19,21), median OS was not reached in 2 other reports after a median follow-up of 13–17 mo (17,20), and 1 large retrospective multicenter evaluation yielded an extraordinarily long median OS of 70 mo (15). Reported symptomatic and biochemical response rates were in the range of 75%–95% (17,19–21) and 45%–67% (17,19,20), respectively. Reported toxicities of clinical relevance were limited (grades 3–4, <15%) and mostly transient.

Patients with a history of previous internal radiation therapies such as PRRT, however, were rare ($n = 4$) in these reported series covering overall more than 300 NET patients (15–18,20,21). Our study confirms efficacy of ⁹⁰Y-RE even in this advanced-metastatic patient group comprising exclusively individuals with reprogression or uncontrolled disease after systemic PRRT. Although radiologic response after 3 mo was less frequent (overall response rate, 30%) than in most series with PRRT-naïve patients (overall response rate, 50%–64%) (15–17,19,21), response is in line with a solid recent single-center report (20) stating a similar response rate of 22.5%.

The OS from the start of ⁹⁰Y-RE observed in our cohort (median OS, 29 mo) appears to be in the lower range of the major NET radioembolization study outcomes (reported median OS, 25–36 mo). The potential negative selection

bias should be kept in mind, because patients with a well-preserved somatostatin-receptor status and good outcome after PRRT would have been retreated with PRRT in our institution; so these individuals with relapsing and refractory disease obviously comprise a negatively selected cohort. Nevertheless, when calculated from the start of PRRT, the median OS in our series reaches 54 mo (95% CI, 47–61 mo). The only predictor of survival in this small cohort was the tumor proliferation index Ki-67 (Fig. 2B), whereas the other baseline factors, including age, performance status, tumor type, hepatic tumor load, presence of extrahepatic disease, tumor response, and previous cumulative activity of ¹⁷⁷Lu-octreotate, did not affect survival in the univariate analysis. Remission status after ⁹⁰Y-RE had only a mild predictive trend, with a median OS not reached after 41 mo in patients experiencing a partial response as opposed to a median OS of 12 mo for the remaining patients (with stable or progressive disease). The lack of significance might be explained by the group of stable-disease patients for whom NETs with a less overt tendency toward morphologic response (i.e., tumor shrinkage) were likely to be less rapidly proliferating and of the G1–G2 carcinoid type. A group of patients with this type of NETs had a potentially better long-term prognosis than those with responsive but higher

proliferating tumors. However, the validity of the entire parameter exploration is obviously limited by the small patient number and considerable amount of variables.

Proposed risk factors for the development of serious toxicity after radioembolization are previous chemo- or intraarterial therapy, young age, and high applied activities relative to the targeted liver volume (7,9,10). In our cohort, serious toxicity (grade 4) did not occur, despite the frequency of advanced liver infiltration (>50% tumor load in 47.8% of patients), high activities per target liver tissue (mean, 1.8 GBq/L of target liver volume; 56.5% of patients with >1.5 GBq/L of target volume), and preexposure to internal radiation. In addition, 10 of 23 patients (53.5%) were pretreated with systemic or transarterial chemotherapy. One explanation for the lack of toxicity may be the hypervascular nature of NET, leading to pronounced preferential tumor-targeted flow and microsphere accumulation with sparing of healthy liver tissue. Our data suggest that ^{90}Y -RE is a safe option in NET patients even after treatment with PRRT.

Hepatic radiation exposure in PRRT has generally not been seen as a concern for liver function (1,31,32). Reported absorbed doses of healthy liver tissue were mainly in the range of 0.1–0.3 Gy/GBq for ^{177}Lu -based PRRT (33–35) and 0.5–1.0 Gy/GBq for ^{90}Y -based PRRT (36–38). For our cohort, the cumulative organ dose to the healthy liver is estimated to be in the range of 2–12 Gy. To allow the addition of the ^{177}Lu -octreotate- and ^{90}Y -RE-associated doses, the biologic equivalent dose formalism would have to be used and respective values calculated (39,40), possibly allowing future toxicity prediction in multiple repeated PRRT or radioembolization treatment settings if a database for dose–toxicity relations were established for both treatment modalities. We speculate that the minor toxicologic relevance of liver-absorbed doses by ^{177}Lu -based PRRT should translate well to ^{90}Y -based PRRT, which will presumably be supported by future safety data.

The preferable treatment sequence (PRRT followed by ^{90}Y -RE vs. ^{90}Y -RE followed by PRRT) remains a matter of discussion. One may argue that liver-directed treatment such as ^{90}Y -RE should be performed as long as tumor involvement is liver-dominant and PRRT is kept in reserve for later stages with more widespread disease. The argument for the reverse sequence is that radioembolization works also in less differentiated NET, whereas effective PRRT depends on pronounced somatostatin receptor overexpression subjected to a potential decline during the course of tumor disease. The ease of use and absence of risk of serious toxicity make PRRT the first-choice modality in somatostatin receptor-positive NET that is uncontrolled or progressive under somatostatin analog treatment, but there certainly is a need for individualized treatment, discussion, and decision making based on various factors, including the patient's preference.

The retrospective nature of this study is an obvious limitation for estimating efficacy and toxicity. However, these initial results provide the first evidence of safety for ^{90}Y radioembolization in patients with a history of PRRT. Pro-

spective trials evaluating the benefit and safety of this sequence would be desirable to confirm these preliminary data. Also, the clinical benefit would be better determined using standardized quality-of-life assessment tools, such as the QoL-C30 or other NET-specific questionnaires. Another limitation is the absence of dosimetric data involved in this analysis. The establishment of a dose–toxicity relationship based on the healthy liver-absorbed dose from PRRT and radioembolization would be highly desirable, but with the lack of toxicity observed in our cohort this aim seems to be difficult to achieve.

CONCLUSION

^{90}Y -RE is safe in patients with advanced liver-dominant NET and a history of internal radiation exposure by PRRT. ^{90}Y -RE can be effective in inducing clinical, biochemical, and morphologic response even after the failure of potent systemic radiopeptide treatment. The lack of relevant liver toxicity despite high applied ^{90}Y activities and considerable previous cumulative activities of ^{177}Lu -octreotate is noteworthy and disputes internal radiation exposure by PRRT as a toxicity risk factor in subsequent radioembolization. The observed outcome in this significantly pretreated and negatively preselected population with overall advanced disease (>50% hepatic tumor burden in almost half of the patients) shows that radioembolization may clearly provide a salvage option for developed resistance to receptor-mediated internal radiation and suggests that PRRT be given before ^{90}Y -RE as a feasible sequence.

DISCLOSURE STATEMENT

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

ACKNOWLEDGMENT

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. *Endocr Relat Cancer*. 2010;17:R53–R73.
2. Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. *Neuroendocrinology*. 2012;95:157–176.
3. Kam BL, Teunissen JJ, Krenning EP, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. *Eur J Nucl Med Mol Imaging*. 2012;39(suppl 1):S103–S112.
4. Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. *Semin Nucl Med*. 2010;40:105–121.
5. Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Integrating radioembolization (^{90}Y microspheres) into current treatment options for liver tumors: introduction to the international working group report. *Am J Clin Oncol*. 2012;35:81–90.
6. Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. *J Vasc Interv Radiol*. 2009;20:1121–1130, quiz 1131.

7. Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin ⁹⁰Y-microspheres for unresectable hepatic tumors. *Int J Radiat Oncol Biol Phys.* 2009;74:1494–1500.
8. Young JY, Rhee TK, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. *J Vasc Interv Radiol.* 2007;18:1375–1382.
9. Piana PM, Gonsalves CF, Sato T, et al. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. *J Vasc Interv Radiol.* 2011;22:1373–1379.
10. Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. *Cancer.* 2008;112:1538–1546.
11. Salem R, Thurston KG. Radioembolization with ⁹⁰Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. *J Vasc Interv Radiol.* 2006;17:1251–1278.
12. Atwell TD, Charboneau JW, Que FG, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. *Cardiovasc Intervent Radiol.* 2005;28:409–421.
13. Steward MJ, Warbey VS, Malhotra A, Caplin ME, Buscombe JR, Yu D. Neuroendocrine tumors: role of interventional radiology in therapy. *Radiographics.* 2008;28:1131–1145.
14. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. *Ann Surg.* 2010;251:910–916.
15. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin ⁹⁰Y-microspheres: early results in 148 patients. *Am J Clin Oncol.* 2008;31:271–279.
16. Rhee TK, Lewandowski RJ, Liu DM, et al. ⁹⁰Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. *Ann Surg.* 2008;247:1029–1035.
17. Kalinowski M, Dressler M, Konig A, et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. *Digestion.* 2009;79:137–142.
18. Cao CQ, Yan TD, Bester L, Liauw W, Morris DL. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. *Br J Surg.* 2010;97:537–543.
19. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. *Cancer.* 2008;113:921–929.
20. Paprottka PM, Hoffmann RT, Haug A, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. *Cardiovasc Intervent Radiol.* 2012;35:334–342.
21. Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. *Int J Radiat Oncol Biol Phys.* 2012;83:887–894.
22. Murthy R, Kamat P, Nunez R, et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. *J Vasc Interv Radiol.* 2008;19:145–151.
23. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. *Int J Radiat Oncol Biol Phys.* 2007;68:13–23.
24. Giammarile F, Bodei L, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. *Eur J Nucl Med Mol Imaging.* 2011;38:1393–1406.
25. Ezziddin S, Opitz M, Attasi M, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. *Eur J Nucl Med Mol Imaging.* 2011;38:459–466.
26. Ezziddin S, Sabet A, Heinemann F, et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with ¹⁷⁷Lu-octreotate. *J Nucl Med.* 2011;52:1197–1203.
27. Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with ⁹⁰Y, ¹¹¹In and ¹⁷⁷Lu at high specific activities. *Eur J Nucl Med Mol Imaging.* 2003;30:917–920.
28. Breeman WA, van der Wansel K, Bernard BF, et al. The addition of DTPA to [¹⁷⁷Lu-DOTA₀Tyr₃]octreotate prior to administration reduces rat skeleton uptake of radioactivity. *Eur J Nucl Med Mol Imaging.* 2003;30:312–315.
29. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastroentero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [¹⁷⁷Lu-DOTA(0),Tyr₃]octreotate. *Eur J Nucl Med Mol Imaging.* 2003;30:417–422.
30. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [¹⁷⁷Lu-DOTA₀Tyr₃]octreotate in patients with endocrine gastroenteropancreatic tumors. *J Clin Oncol.* 2005;23:2754–2762.
31. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. *Neuroendocrinology.* 2009;90:220–226.
32. Bodei L, Cremonesi M, Grana CM, et al. Yttrium-labelled peptides for therapy of NET. *Eur J Nucl Med Mol Imaging.* 2012;39(suppl 1):S93–S102.
33. Cremonesi M, Botta F, Di Dia A, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. *Q J Nucl Med Mol Imaging.* 2010;54:37–51.
34. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [¹⁷⁷Lu-DOTAOTyr₃]octreotate: comparison with [¹¹¹In-DTPA₀]octreotide in patients. *Eur J Nucl Med.* 2001;28:1319–1325.
35. Sandström M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with ¹⁷⁷Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. *Eur J Nucl Med Mol Imaging.* 2010;37:212–225.
36. Forrer F, Uusijarvi H, Waldherr C, et al. A comparison of ¹¹¹In-DOTATOC and ¹¹¹In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. *Eur J Nucl Med Mol Imaging.* 2004;31:1257–1262.
37. Helisch A, Forster GJ, Reber H, et al. Pre-therapeutic dosimetry and biodistribution of ⁸⁶Y-DOTA-Phe1-Tyr₃-octreotide versus ¹¹¹In-pentetreotide in patients with advanced neuroendocrine tumours. *Eur J Nucl Med Mol Imaging.* 2004;31:1386–1392.
38. Förster GJ, Engelbach MJ, Brockmann JJ, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of ⁸⁶Y-DOTATOC and ¹¹¹In-DTPA-octreotide. *Eur J Nucl Med.* 2001;28:1743–1750.
39. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. *J Nucl Med.* 2006;47:1467–1475.
40. Cremonesi M, Ferrari M, Bartolomei M, et al. Radioembolisation with ⁹⁰Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. *Eur J Nucl Med Mol Imaging.* 2008;35:2088–2096.



The Journal of
NUCLEAR MEDICINE

^{90}Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy

Samer Ezziddin, Carsten Meyer, Stanislava Kahancova, Torjan Haslerud, Winfried Willinek, Kai Wilhelm, Hans-Jürgen Biersack and Hojjat Ahmadzadehfar

J Nucl Med. 2012;53:1663-1669.

Published online: September 17, 2012.

Doi: 10.2967/jnumed.112.107482

This article and updated information are available at:
<http://jnm.snmjournals.org/content/53/11/1663>

Information about reproducing figures, tables, or other portions of this article can be found online at:
<http://jnm.snmjournals.org/site/misc/permission.xhtml>

Information about subscriptions to JNM can be found at:
<http://jnm.snmjournals.org/site/subscriptions/online.xhtml>

The Journal of Nuclear Medicine is published monthly.
SNMMI | Society of Nuclear Medicine and Molecular Imaging
1850 Samuel Morse Drive, Reston, VA 20190.
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)

© Copyright 2012 SNMMI; all rights reserved.

The logo for the Society of Nuclear Medicine and Molecular Imaging (SNMMI) consists of the letters 'S', 'N', 'M', and 'I' arranged in a 2x2 grid. Each letter is white and set within a red square. To the right of this grid, the text 'SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING' is written in a smaller, black, sans-serif font, stacked in three lines.
SOCIETY OF
NUCLEAR MEDICINE
AND MOLECULAR IMAGING